Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
AZD 1390 is an inhibitor of Ataxia-telangiectasia mutated (ATM) kinase (IC50 = 0.78 nM).1 It is selective for ATM over Ataxia-telangiectasia and Rad3-related protein/kinase (ATR), PI3K, mammalian target of rapamycin (mTOR), and DNA protein kinase (DNA-PK; IC50s = >30, >12, >16, and >29.9 µM, respectively). AZD 1390 (10 nM) sensitizes glioma cells expressing mutant, but not wild-type, p53 to ionizing radiation. Oral administration of AZD 1390 (20 mg/kg twice daily), in combination with radiation, reduces the growth of brain metastases and increases survival in an NCI H2228 lung carcinoma mouse xenograft model.
WARNING This product is not for human or veterinary use.
1. The brain-